Longitudinal clinical and functional pulmonary follow-up after megatherapy, fractionated total body irradiation, and autologous bone marrow transplantation for metastatic neuroblastoma

Medical and Pediatric Oncology

Volumn 32, Issue 3, 1999, Pages 170-176

  Neve V ^a   Foot, A B M ^b   Michon, J ^b   Fourquet, A ^b   Zucker, J M ^b   Boule M ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

Autologous bone marrow transplantation; Chemotherapy; Neuroblastoma; Pulmonary function; Total body irradiation

Indexed keywords

BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INTERLEUKIN 2; RETINOIC ACID; VINCRISTINE;

ANTIBODY SPECIFICITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; LUNG COMPLIANCE; LUNG FUNCTION; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0344096756     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199903)32:3<170::AID-MPO2>3.3.CO;2-W     Document Type: Article

References (42)

1. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Cancer 1971;27:374-378.
2. Pinkerton R, Philip T, Bouffet E, et al. Autologous bone marrow transplantation in pediatric solid tumors. Clin Hematol 1986;15: 187-203.
3. Philip T, Bernard JL, Zucker J-M, et al. High dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of Stage IV patients over 1 year of age. J Clin Oncol 1987;5:260-267.
4. Zucker J-M, Philip T, Bernard JL. Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of the LMCE3 study in 40 patients. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC, editors. Advances in neuroblastoma research 3. New York: Wiley-Liss, Inc.; 1991. p 543-551.
5. Philip T, Ladenstein R, Zucker J-M, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993;67:119-127.
6. Ettinger NA, Trulock EB. State of the art. Pulmonary complications of organ transplantation. Part 2. Am Rev Respir Dis 1991; 144:213-223.
7. Cooper JAD Jr, White DA, Matthay RA. State of art. Drug-induced pulmonary disease. Am Rev Respir Dis 1986;133:321-340.
8. Gross NJ. Pulmonary effects of radiation therapy. Review. Ann Intern Med 1977;86:81-92.
9. Wohl ME, Griscom NT, Traggis DG, et al. Effects of therapeutic irradiation delivered in early childhood upon subsequent lung function. Pediatrics 1975;55:507-516.
10. Benoist M-R, Lemerle J, Jean R, et al. Effects on pulmonary function of whole lung irradiation for Wilms tumor in children. Thorax 1982;37:175-180.
11. Boulé M, Zucker J-M, Gaultier C, et al. Lung function of children treated for malignant extrapulmonary tumors. Bull Eur Physiopathol Respir 1984;20:121-126.
12. Miller RW, Fusner JE, Fink RJ, et al. Pulmonary function abnormalities in long-term survivors of childhood cancer. Med Pediatr Oncol 1986;14:202-207.
13. Makipernaa A, Heino M, Laitinen LA, et al. Lung function following treatment of malignant tumors with surgery, radiotherapy, or cyclophosphamide in childhood. A follow-up study after 11 to 27 years. Cancer 1989;63:625-630.
14. Attard-Montalto SP, Kingston JE, Eden OB, et al. Late follow-up of lung function after whole lung irradiation for Wilms' tumor. Br J Radiol 1992;66:1114-1118.
15. Pinkerton CR, Zucker J-M, Hartmann O, et al. Short duration, high dose intensity induction chemotherapy in advanced neuroblastoma. Is there any therapeutic gain? Br J Cancer 1990;62:319-323.
16. Gaultier C, Boulé M, Pappo A, et al. Résistance pulmonaire totale, compliance pulmonaire dynamique (chez, l'enfant de 3 à 15 ans). Principe, discussion des valeurs normales, intérêt de la mesure. Sem Hôp Paris 1974;50:1045-1052.
17. Guenard H, Chaussain M. A sampling method for mean alveolar gas in normal subjects and patients with respiratory disease. Bull Eur Physiopathol Respir 1976;12:625-636.
18. Quanjer PH, Helms P, Bjure J, et al. Standardization of lung function tests in pediatrics. Eur Respir J 1989;2:121S-264S.
19. Gaultier C, Boulé M, Allaire Y, et al. Growth of lung volumes during the first three years of life. Bull Eur Physiopathol Respir 1979;15:1103-1116.
20. Taussig LM, Harris TR, Lebowitz MD. Lung function in infants and young children. Am Rev Respir Dis 1977;116:233-239.
21. Boulé M, Gaultier C, Girard F. Lung transfer carbon monoxide during the first three years of life. Bull Eur Physiopathol Respir 1986;22:467-471.
22. Chaussain M, Denjean A, Lebeau C, et al. Lung transfer factor for CO at rest in normal children by a steady state method. Bull Eur Physiopathol Respir 1982;18:411-417.
23. Laird NM, Ware JH. Random effect model for longitudinal data. Biometrics 1982;38:963-974.
24. Shiobara S, Harada M, Mori T, et al. Difference in post-transplant recovery of immune reactivity between allogeneic and autologous bone marrow transplantation. Transplant Proc 1982;2:429-433.
25. Aronin PA, Mahaley MS, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. An assessment of risk factors. N Engl J Med 1980;303:183-188.
26. O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990;323:378-382.
27. Alvarado CS, Boat TF, Newman AJ. Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide. J Pediatr 1978;92(3):443-446.
28. Taetle R, Dickman PS, Feldman PS. Pulmonary histopathological changes associated with melphalan therapy. Cancer 1978;42: 1239-1245.
29. Goucher G, Rowland V, Hawkins J. Melphalan-induced pulmonary interstitial fibrosis. Chest 1980;77:805-806.
30. Commers JR, Foley JF. Pulmonary hyaline membrane disease occurring in the course of VM26 therapy. Cancer Treat Rep 1979; 63:2093-2095.
31. Quigley PM, Yeager AM, Loughlin GM. The effect of bone marrow transplantation on pulmonary function in children. Pediatr Pulmonol 1994;18:361-367.
32. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989;1:7-20.
33. Villani F, Galimberti M, Rizzi M, et al. Pulmonary toxicity of recombinant interleukin-2 plus lymphokine-activated killer cell therapy. Eur Respir J 1993;6:828-833.
34. Michon J, Négrier S, Coze C, et al. Administration of high dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-East of France Group study. In: Evans AE, D'Angio G, Knudson A, Seeger RC, editors. Advances in neuroblastoma research 4. New York: Wiley-Liss, Inc.; 1994. p 293-300.
35. Kaplan EB, Wodell RA, Wilmott RW, et al. Chronic graft-versus-host disease and pulmonary function. Pediatr Pulmonol 1992;14: 141-148.
36. Serota FT, August CS, Koch PA, et al. Pulmonary function in patients undergoing bone marrow transplantation. Med Pediatr Oncol 1986;12:137-163.
37. Litttman P, Eadows AT, Polgar G, et al. Pulmonary function in survivors of Wilms tumor. Patterns of impairment. Cancer 1976; 37:2773-2776.
38. Depledge MH, Barret A, Powles RL. Lung function after bone marrow grafting. Int J Radiat Oncol Biol Phys 1983;9:145-151.
39. Clark JG, Crawford SW, Madtes DK, et al. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989;111:368-376.
40. Sutedja TG, Apperley JF, Hughes JM, et al. Pulmonary function after bone marrow transplantation for chronic myeloid leukemia. Thorax 1988;43:163-169.
41. Tait RC, Burnett AK. Robertson AG, et al. Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease. Int J Radiat Oncol Biol Phys 1991;20: 1219-1227.
42. Ellis ER, Marcus RB, Cicale MJ, et al. Pulmonary function after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma. J Clin Oncol 1992;10:459-463.